Ads
related to: niaspan prescribing information for adults with cancer patients- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Request Samples
Get patients started
with a 14-day sample
- Trial Results
See Clinical Data
and Trial
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Patient Identification
View a Patient Profile
to Learn More
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Colesevelam is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia as monotherapy and to improve glycemic control in adults with type 2 diabetes mellitus, [4] including in combination with a statin.
Prescription immediate release (Niacor) and extended release (Niaspan) nicotinic acid are contraindicated for people with either active or a history of liver disease because both, but especially Niaspan, have been associated with instances of serious, on occasion fatal, liver failure.
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product.
Nabiximols has also been studied for cancer pain resistant to opioids. While adjuvant use of nabiximols was safe in 3 trials for cancer pain, [22] [23] [24] data regarding efficacy were mixed, and the drug failed to meet its primary endpoint for this purpose in its first Phase III trial. [25]
According to the government, Cephalon promoted Actiq for use in non-cancer patients to treat such conditions as migraines, sickle-cell pain crises, and other injuries. [16] Gabitril , meanwhile, received FDA approval as a treatment for partial seizures, but the manufacturer allegedly marketed the drug for anxiety, insomnia, and pain. [ 16 ]
Cancer pain relief. With a guide to opioid availability (2 ed.). Geneva: WHO. ISBN 92-4-154482-1. World Health Organization (1998). Cancer pain relief and palliative care in children. Geneva: WHO. ISBN 978-92-4-154512-9. "WHO's cancer pain ladder for adults". Cancer. WHO. 2017. Archived from the original on August 7, 2003
According to research cited in the FDA’s prescribing information for Ozempic, ... compared to just 39 patients on a placebo. While many people with gallstones may not experience symptoms, it’s ...
The Beers Criteria are intended to serve as a guide for clinicians and not as a substitute for professional judgment in prescribing decisions. The criteria may be used in conjunction with other information to guide clinicians about safe prescribing in older adults. [5] [non-primary source needed] [6] [non-primary source needed].